Governance
Conflicts of Interest
Released: · Last reviewed:
A conflict of interest exists when a financial, personal, or professional relationship could reasonably be expected to influence published judgement. Tirzepatide Editorial is affiliate-supported, and the only commercial relationship the publisher has disclosed is an affiliate/referral relationship with NexLife, disclosed September 4, 2026. NexLife is also the site's #1 editorial pick under methodology v4.1 — a conflict this page names rather than leaves implicit. Reviewers disclose relevant relationships before reviewing any page.
Key takeaways
- The site is affiliate-supported; a general disclosure in the footer of every page says so.
- The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04); the details are being confirmed with the publisher.
- NexLife is the site's #1 editorial pick, scored 94/100 under the v4.1 weighted rubric, while other providers await scoring — readers should weigh the relationship when reading about NexLife.
- Price tables are sorted by published price under the price-classification rule; there NexLife is not the lowest.
- Reviewers disclose relevant relationships before reviewing, and recuse where one exists.
- Trial sponsorship by manufacturers is disclosed on every trial page.
| Publisher financial interests in covered companies | One disclosed: an affiliate/referral relationship with NexLife (since 2026-09-04) |
|---|---|
| Affiliate, referral, or sponsorship income | Affiliate-supported; NexLife is the only disclosed commercial relationship; no sponsorship |
| Reviewer disclosure | Required before review; recusal where a relationship exists |
| Trial funding disclosure | Stated on every trial page |
| Ranking method | Methodology v4.1 — seven published weighted categories for the editorial ranking; price tables sorted by published price |
Why disclose trial sponsorship if the results are peer-reviewed?
Because sponsorship shapes what gets studied, how endpoints are chosen, and which results are published, even when the reported analysis is sound. The SURMOUNT and SURPASS programmes were funded by the manufacturer. That does not invalidate them — they are large, randomised, and published in major journals — but a reader is entitled to know it without hunting for it.
How does the editorial score handle conflict risk?
A weighted editorial score is the easiest place for preference to hide, because the weights are chosen and the result looks objective. From September 4 to November 7, 2026 this site avoided one by ordering providers strictly by computed cost. Since November 8, 2026 it uses the v4.1 weighted rubric — pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10 — under which NexLife, the disclosed commercial partner, scores 94/100 and is the #1 pick. The mitigations are partial: the weights are published, price tables remain sorted by price so the cost picture can be checked separately from the score, and other providers are listed alphabetically without rank numbers until they are scored.
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Publisher, staff, reviewer, provider and pharmacy and financial conflicts, organised around the primary question of tirzepatide conflicts of interest. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Publisher | Covered on this page | Regulatory or policy source |
| Staff | Covered on this page | Regulatory or policy source |
| Reviewer | Covered on this page | Regulatory or policy source |
| Provider | Covered on this page | Regulatory or policy source |
| Pharmacy and financial conflicts | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide conflicts of interest.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Do you have financial ties to any provider?
The site is affiliate-supported. The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04); the full details are being confirmed with the publisher.
Are trials funded by manufacturers?
Yes — the SURMOUNT and SURPASS programmes were sponsored by Eli Lilly, disclosed on every trial page.
What happens if a reviewer has a relationship with a company?
They disclose it and recuse from reviewing content concerning that company.
How do rankings avoid bias?
Not entirely. The editorial ranking uses the published v4.1 rubric, under which NexLife — the disclosed commercial partner — scores 94/100; other providers have not yet been scored. Price tables are sorted by published price, and records without a comparable price are listed with the reason.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
| 2026-11-08 | Conflicts restated: the site is affiliate-supported; the statements that rankings are computed with no editorial score, that NexLife moved to third on committed cost, and that no provider has any financial tie were replaced by the v4.1 weighted rubric (NexLife #1, 94/100, disclosed as the commercial partner) and by what the publisher has disclosed. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.